Hypersensitivity to neomycin & polymyxin. Postpone vaccination in patients suffering from acute severe febrile illness. Not to be administered as IV. Does not protect against diseases caused by other types of
H. influenzae nor against meningitis caused by other organisms. History of febrile convulsions; family history of convulsions, sudden infant death syndrome & adverse event following DPT, IPV &/or HIB vaccination. Patients w/ thrombocytopenia or bleeding disorder. Immunosuppressed patients eg, on immunosuppressive therapy. Syncope. Excretion of capsular polysaccharide antigen in urine. Perform review of medical history & clinical exam before vaccination. Carefully consider giving subsequent dose of pertussis-containing vaccine in patients w/ rectal temp ≥40°C, collapse or shock-like state (hypotonic-hyporesponsive episode), persistent, inconsolable crying lasting ≥3 hr w/in 48 hr of vaccination; convulsions w/ or w/o fever occurring w/in 3 days of vaccination. Defer pertussis immunization in childn w/ progressive neurological disorders eg, infantile spasms, uncontrolled epilepsy or progressive encephalopathy. Pregnancy & lactation. Potential risk of apnoea & consider need for resp monitoring for 48-72 hr in very premature infants (≤28 wk gestation) & those w/ previous history of resp immaturity. Not recommended in adults, adolescents or childn >5 yr.
Sign Out
6234fed9-82f6-4b2a-873b-a5b400e1a1f8.GIF)
